Telus Health, Maple and the Private-Medicine Debate Inside Canada’s Public System

The private-medicine debate in Canada is not about whether private companies deliver care, since they always have, but about who pays and who is allowed to charge. Telus Health, Maple and LifeLabs sit on different sides of that line. Telus’s membership clinics and Maple’s paid virtual visits have drawn provincial and federal scrutiny under the Canada Health Act; LifeLabs, by contrast, bills provincial insurers and is uncontroversial despite being owned successively by a pension fund and a US laboratory chain. This article explains what the Act actually permits, how the three businesses are structured and financed, what the regulators have done since 2023, and where the money is going in 2026. It is part of the Canada Company Stories hub.

What does the Canada Health Act actually prohibit?

The Canada Health Act of 1984 does not ban private healthcare; it conditions federal cash transfers to provinces on five criteria, public administration, comprehensiveness, universality, portability and accessibility, and on the absence of extra-billing and user charges for insured services. Insured services are medically necessary hospital and physician care. Where a province allows patients to be charged for those, Section 20 requires Ottawa to deduct the amount charged from the province’s Canada Health Transfer, dollar for dollar.

Everything else is grey or open. Prescription drugs outside hospital, dental care, physiotherapy, psychology, most nurse-practitioner and pharmacist services, employer-sponsored benefits and anything cosmetic or elective fall outside the Act’s definition, which is why Canada has large private insurance and benefits industries alongside its public system. Roughly 30 per cent of Canadian health spending is private, a higher share than in most European universal systems.

The Act also says nothing about who delivers insured care. Most family doctors are private businesses billing the provincial plan, and private clinics have long performed publicly funded surgery and imaging under contract. The dispute arises when a private provider charges the patient, or a membership fee, for access to a doctor or a test that the public plan would otherwise pay for.

How did Telus, a telecom, become Canada’s largest health technology company?

Telus Health began in 2007 when Telus bought Emergis, a Montreal electronic-claims and health-records company, for about C$763 million, and spent the next fifteen years assembling clinics, pharmacy software, electronic medical records and benefits administration. Former chief executive Darren Entwistle argued that a telecom’s networks, data and billing relationships were a natural platform for digital health, and Telus became the dominant vendor of physician EMR systems in several provinces and the processor of about 130 million insurance claims a year.

The transformational deal was LifeWorks, the former Morneau Shepell, acquired in 2022 for about C$2.3 billion in equity, or roughly C$2.9 billion including debt. LifeWorks brought employee and family assistance programmes, pension and benefits administration and a global footprint, turning Telus Health from a Canadian software and clinic business into an international employer-services company. Telus reported in February 2026 that the LifeWorks integration had delivered C$431 million of annualised synergies, nearly three times the original target, split between C$334 million of cost savings and C$97 million of cross-selling revenue.

Further acquisitions followed, including Workplace Options in the second quarter of 2025, which added tens of millions of covered lives. By the end of 2025 Telus Health reported 161.2 million lives covered worldwide, up 85 million in twelve months, though most of that increase came from the acquisition and a definition change that counts clients who use Telus Health services indirectly.

How is Telus Health performing financially in 2026?

Telus Health is growing, but slowly and with costs attached. In the fourth quarter of 2025 operating revenue was C$540 million, up 13 per cent, and adjusted EBITDA rose 10 per cent to C$96 million. In the second quarter of 2026 health services revenue grew 4 per cent to C$533 million, adjusted EBITDA was C$99 million, up 1 per cent, and reported EBITDA fell 17 per cent to C$75 million because of restructuring costs. Lives covered stood at 158.9 million, up about 1 per cent net of churn, with organic growth in payor and provider solutions offset by a decline in employer solutions.

The segment is a small part of Telus overall, which reported second-quarter 2026 consolidated revenue of C$4.9 billion, a net loss of C$1.8 billion after a C$2.1 billion impairment of Telus Digital, and a 55 per cent reset of its dividend to an annualised C$0.75 a share, aimed at saving about C$2.7 billion through 2028 for debt reduction. Leverage was 3.5 times EBITDA against a target of 3.0 times or lower by the end of 2028.

That context explains why Telus Health is in play. In February 2026 Telus said it had engaged financial advisers to explore strategic partnership opportunities for the unit, describing it as well positioned to attract partners that would unlock value for shareholders. In July 2026, with Victor Dodig newly installed as chief executive after Entwistle’s retirement on 30 June, the company said it was in discussions with interested parties about non-core Telus Health assets. A partial sale to a pension fund or private-equity investor, of the kind Canada’s large pension funds routinely make, would bring cash to a parent that needs it.

Why did Telus Health’s clinics attract regulators’ attention?

The flashpoint was Telus Health Care Centres’ LifePlus programme, a preventive-health membership reported to cost several thousand dollars a year that included access to family physicians. In late 2022 and 2023 British Columbia’s Medical Services Commission reviewed whether the programme amounted to charging for insured services, and the federal health minister at the time, Jean-Yves Duclos, wrote to provinces warning that charges for medically necessary care, including care delivered virtually or by nurse practitioners, would attract transfer deductions. Telus said its membership fees covered uninsured preventive services and that insured physician visits were billed to the public plan.

The outcome was a negotiated clarification rather than a penalty: Telus adjusted how LifePlus was marketed and billed in British Columbia, and the episode became the reference case for how far membership medicine can go. Ottawa has since gone further. In 2023 it issued a Diagnostic Services Policy, effective from April 2026, bringing privately charged medically necessary diagnostic imaging into the deduction regime, and in January 2025 it announced a Canada Health Act Services Policy extending the same principle to medically necessary services delivered by nurse practitioners and other non-physician providers, with deductions to follow from 2026.

Quebec’s physicians’ college and Ontario’s health ministry have separately examined clinics charging block fees or membership fees, and Ontario in 2024 tightened rules on charging for access to primary care. The pattern is consistent: regulators tolerate fees for services the public plan does not cover and act when a fee becomes a condition of seeing a doctor for something it does.

How does Maple make money selling doctor visits in a free system?

Maple, founded in Toronto in 2015 by emergency physician Brett Belchetz with Roxana Zaman and Stuart Starr, connects patients to doctors and nurse practitioners by video and text within minutes. It charges per visit or through membership, with a family plan priced at C$85 a month in 2026 and separate fees for specialist consultations; it says eight million Canadians have access to its service, mostly through employers and insurers, and that it has delivered 3.2 million visits with more than 2,000 practitioners.

The business works because of two features of the public system. First, several provinces do not pay physicians for virtual visits with patients they have no existing relationship with, or pay less than for in-person visits, so a doctor working for Maple is providing a service the public plan does not fully insure. Second, millions of Canadians have no family doctor, and employers are willing to pay for access as a benefit. Maple’s investors include Shoppers Drug Mart, part of the Loblaw group, SE Health, Royal Bank of Canada and Acton Capital, and it has also won public contracts to supply virtual care to hospitals and provincial programmes.

Critics, including some provincial medical associations, argue that paid virtual care is two-tier medicine by another name and pulls doctors out of public primary care. Maple’s answer is that it operates where the public plan does not, and that its public-sector contracts show the model can serve both. Ottawa’s 2025 services policy, which treats medically necessary care by nurse practitioners as insured for deduction purposes, tightens the space in which Maple and similar platforms can charge patients directly, pushing them further toward employer and government customers.

Why was LifeLabs sold, and why did nobody object?

LifeLabs is Canada’s largest community laboratory, performing blood and specimen tests for patients in Ontario, British Columbia and Saskatchewan under contracts with provincial plans. OMERS, the Ontario municipal employees’ pension fund, bought it in 2007 and consolidated it with other labs; in July 2024 it agreed to sell the company to Quest Diagnostics of New Jersey for about C$1.35 billion including net debt. Quest expected the business to contribute about C$970 million of annual revenue and said more than 8 million Canadians had used LifeLabs’ online results portal.

The sale drew little political reaction, which is instructive. LifeLabs does not charge patients for insured tests; it bills the province at negotiated rates, so a change of owner from a Canadian pension fund to a US corporation did not alter who pays. Provincial regulators approved the deal, and the main public concern was data, given LifeLabs’ 2019 breach affecting about 15 million customers, for which it later settled a class action.

The contrast with Telus and Maple shows where the real line lies in Canadian health politics. Private ownership of providers is accepted; private billing of patients for insured care is not. A foreign-owned lab chain is less controversial than a Canadian telecom’s membership clinic.

What has Ottawa done about private fees since 2023?

Federal enforcement has become more active after a long period of near-dormancy. Health Canada’s annual Canada Health Act reports show deductions in the tens of millions of dollars in recent years, mainly for patient charges at private surgical and imaging clinics, with the largest amounts historically levied on British Columbia and Quebec. Deductions are refundable if the province eliminates the charges, which gives provinces an incentive to act.

Two policy instruments now extend the regime. The Diagnostic Services Policy, announced in 2023 and applied to deductions from April 2026, treats patient charges for medically necessary MRI and CT scans at private clinics as extra-billing. The Canada Health Act Services Policy, announced in January 2025, applies the same logic to medically necessary services delivered by nurse practitioners, pharmacists and other regulated professionals, which closes the loophole that allowed virtual-care platforms and clinics to charge for a nurse-practitioner appointment that would have been free with a physician.

The courts have been less helpful to private-medicine advocates. The Supreme Court of Canada’s 2005 Chaoulli decision struck down Quebec’s ban on private insurance for insured services, but only under the Quebec charter, so it did not spread. The Cambie Surgeries case in British Columbia, brought by surgeon Brian Day, ended when the Supreme Court declined in 2023 to hear an appeal against the provincial courts’ rulings upholding the ban on private billing. The legal structure of medicare is, for now, settled.

Where does this leave Telus Health’s strategic review?

Telus’s options for its health unit are shaped by what it is actually worth to different buyers. The employer-services business built from LifeWorks has stable, contracted revenue and international scale, and would suit a pension fund or private-equity owner; it is also the part that competes with global benefits providers rather than with medicare. The Canadian clinics, pharmacy and EMR businesses are more regulated, more political and more tied to Telus’s domestic brand.

The July 2026 language about non-core assets suggests Telus may sell pieces rather than the whole, retaining the software and data businesses that connect to its telecom relationships. Any transaction will be judged against the LifeWorks price: Telus paid about C$2.3 billion plus debt in 2022 for a business whose synergies it has now largely realised, and a partner coming in at a higher valuation would validate Entwistle’s thesis, while a sale below it would confirm what sceptics argued at the time.

For the wider market, the review tests whether Canadian institutional investors will fund private health services at scale. Pension funds such as OMERS have already shown they will own labs and clinics; the question is whether they will pay telecom-style multiples for a business whose regulatory perimeter is still being drawn. Readers interested in how Telus’s telecom core is faring should see our account of the Rogers-Shaw merger and Canadian telecom.

What can founders and investors learn from the private-medicine debate?

The first lesson is to understand the payer map before building the product. Canada’s public plans cover physicians and hospitals and leave most other services to employers, insurers and households. Businesses that serve the uncovered space, employee assistance, mental health, pharmacy, benefits administration, lab testing under contract, have scaled without controversy; businesses that touch physician access have faced reviews, however carefully they are structured.

The second lesson is that acquisitions in services businesses are judged by integration, not announcement. Telus’s LifeWorks deal was questioned on price, but the C$431 million of annualised synergies reported four years later is a genuinely strong result; the problem is that the parent’s balance sheet and the telecom’s share price now force a reckoning that the health unit did not cause. Investors in a subsidiary should watch the parent’s leverage as closely as the subsidiary’s growth.

The third lesson is that regulatory risk in healthcare is political, not just legal. The Cambie case shows courts will not open the system; the deductions regime shows Ottawa will use money to close gaps when the politics demand it. Companies like Apotex, which lives inside Canada’s drug-pricing rules, or the cannabis producers squeezed by excise policy, learned the same thing in other corners of the health economy. For a contrast with a country where private supplementary insurance is a settled part of universal coverage, see the Australia Company Stories hub.

Frequently Asked Questions